Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Business Combination, Contingent Consideration, Liability $ 4,476,000  
Net (loss) income (8,605,000) (899,000)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 1,328,000 922,000
Realignment accrual accretion 106,000 106,000
Provision for bad debt 0 9,000
Stock-based compensation 1,764,000 1,519,000
Other changes in assets and liabilities:    
(Increase) decrease in accounts receivable (981,000) 6,658,000
Decrease (increase) in unbilled costs 1,644,000 (4,690,000)
Decrease in other current assets 1,752,000 2,330,000
Decrease in other long-term assets (9,000) 0
Decrease in accounts payable 501,000 (1,620,000)
Decrease in unearned contract revenue (1,768,000) (2,483,000)
(Decrease) increase in accrued salaries and bonus (2,830,000) 957,000
Decrease in other accrued expenses 186,000 (1,620,000)
Decrease in long-term liabilities (1,054,000) (952,000)
Net cash used in operating activities (7,966,000) 237,000
Cash Flows From Investing Activities    
Purchase of property and equipment (1,298,000) (1,648,000)
Payments to Acquire Investments   (1,500,000)
Payments to Acquire Productive Assets (8,500,000)  
Loan to the Diagnostic Company (655,000) 0
Net cash used in investing activities (10,453,000) (3,148,000)
Cash Flows From Financing Activities    
Payments for Repurchase of Common Stock (215,000) (245,000)
Net cash used in financing activities (215,000) (245,000)
Net increase (decrease) in cash and cash equivalents (18,634,000) (3,156,000)
Cash and cash equivalents – beginning 45,639,000 52,783,000
Cash and cash equivalents – ending $ 27,005,000 $ 49,627,000